Joshua Pinto - May 28, 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
President
Signature
/s/ Michael Milligan, as Attorney-in-Fact for Joshua Pinto
Stock symbol
NMRA
Transactions as of
May 28, 2025
Transactions value $
$0
Form type
4
Date filed
5/30/2025, 06:25 PM
Previous filing
May 23, 2025
Next filing
Nov 13, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Pinto Joshua President C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN /s/ Michael Milligan, as Attorney-in-Fact for Joshua Pinto 2025-05-30 0001992595

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -223K -100% 0 May 28, 2025 Common Stock 223K $1.69 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -271K -100% 0 May 28, 2025 Common Stock 271K $1.69 Direct F2, F3
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -223K -100% 0 May 28, 2025 Common Stock 223K $1.69 Direct F2, F4
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -720K -100% 0 May 28, 2025 Common Stock 720K $1.69 Direct F2, F5
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -127K -100% 0 May 28, 2025 Common Stock 127K $1.69 Direct F2, F6
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -170K -100% 0 May 28, 2025 Common Stock 170K $1.69 Direct F2, F7
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -3M -100% 0 May 28, 2025 Common Stock 3M $1.69 Direct F2, F8
transaction NMRA Stock Option (Right to Buy) Award +223K 223K May 28, 2025 Common Stock 223K $0.72 Direct F1, F2, F9
transaction NMRA Stock Option (Right to Buy) Award +271K 271K May 28, 2025 Common Stock 271K $0.72 Direct F2, F3, F9
transaction NMRA Stock Option (Right to Buy) Award +223K 223K May 28, 2025 Common Stock 223K $0.72 Direct F2, F4, F9
transaction NMRA Stock Option (Right to Buy) Award +720K 720K May 28, 2025 Common Stock 720K $0.72 Direct F2, F5, F9
transaction NMRA Stock Option (Right to Buy) Award +127K 127K May 28, 2025 Common Stock 127K $0.72 Direct F2, F6, F9
transaction NMRA Stock Option (Right to Buy) Award +170K 170K May 28, 2025 Common Stock 170K $0.72 Direct F2, F7, F9
transaction NMRA Stock Option (Right to Buy) Award +3M 3M May 28, 2025 Common Stock 3M $0.72 Direct F2, F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.
F2 On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged.
F3 The option is early exercisable. 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date.
F4 The performance-based stock option becomes exercisable in two tranches upon the achievement of specified stock price milestones. Each tranche shall vest in 24 equal monthly installments measured from the stock price achievement date.
F5 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F6 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F7 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F8 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F9 On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.